Lucknow, India

Ramesh Chander

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2010.


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:

goldMedal1 out of 834,411 
Other
 patents

Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ramesh Chander: Innovator in Antihyperglycemic and Antidyslipidemic Agents

Introduction

Ramesh Chander is a notable inventor based in Lucknow, India. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that exhibit antidiabetic properties. His work focuses on creating innovative solutions to combat hyperglycemia and dyslipidemia.

Latest Patents

Ramesh Chander holds a patent for "Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents." This invention provides appropriately substituted chalcones, represented by a specific structural formula. The compounds are designed with various substituents, including H, OH, O-alkyl, and O-phenyl. The patent highlights the potential of these compounds to exhibit significant antidiabetic effects in various animal models, indicating their promise for further development and exploitation.

Career Highlights

Throughout his career, Ramesh has focused on innovative research that bridges the gap between chemistry and medicine. His dedication to developing effective therapeutic agents has positioned him as a key figure in his field. With a patent count of 1 patent, he continues to contribute to advancements in healthcare.

Collaborations

Ramesh Chander has collaborated with notable colleagues, including Ram Pratap and Mavurapu Satyanarayana. These partnerships have fostered a collaborative environment that enhances the research and development of new medicinal compounds.

Conclusion

Ramesh Chander's work in the field of antihyperglycemic and antidyslipidemic agents showcases his innovative spirit and commitment to improving health outcomes. His contributions are paving the way for future advancements in diabetes treatment.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…